Company overview
OncoHost provides PROphet®, an AI-powered precision oncology platform that analyzes proteomic patterns from a single pre-treatment blood sample to predict clinical benefit, resistance mechanisms, and toxicities in cancer patients. The tool supports clinical decision-making for immunotherapy and combination therapies, particularly in NSCLC, by combining systems biology, bioinformatics, and machine learning. It enables personalized treatment plans to improve patient outcomes and reduce unnecessary therapies.
OncoHost is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include precision oncology, proteomic analysis, ai cancer diagnostics, immunotherapy biomarkers, nsclc treatment.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with OncoHost include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.oncohost.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- precision oncology, proteomic analysis, ai cancer diagnostics, immunotherapy biomarkers, nsclc treatment
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is PROphet® and how does it work?
- PROphet® is OncoHost's proprietary plasma-based proteomic pattern recognition platform that analyzes ~7,000 proteins from one blood sample using AI, systems biology, and machine learning to generate a score predicting clinical benefit and guiding therapy selection.
- What cancers does OncoHost's technology target?
- The platform focuses on precision oncology, with validated applications for NSCLC immunotherapy decisions and broader use in predicting responses to cancer therapies.
- Where is OncoHost located and what are its regulatory achievements?
- Headquartered in Binyamina, Israel, and Cary, North Carolina, USA; PROphet® provides clinically validated scores, named Top Precision Oncology Solution for 2025 by Life Sciences Review.
Related editorial coverage
- FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
- FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
- Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment
- FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
- Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment
- FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib
Explore lab tools and QA/QC resources for R&D teams.
